Publications by authors named "Michael Dechant"

Claim this Profile
O
Opioid substitution treatment, relapse and addiction-related outcomes in prison setting and after release: A longitudinal study.
Kerstin Geißelsöder, Maren Weiss, Klara Boksán, Michael Dechant, Johann Endres

Nordisk Alkohol Nark· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Treatment of Opioid-dependent Inmates - Attitudes and Treatment Practice of medical Staff in Bavarian Prisons].
Maren Weiss, Kerstin Geißelsöder, Maike Breuer, Michael Dechant, Johann Endres

Gesundheitswesen· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Thrombotic Microangiopathies].
Jörg Schubert, Michael Dechant

Dtsch Med Wochenschr· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.
Stefan Lohse, Sebastian Loew, Anna Kretschmer, J H Marco Jansen, Saskia Meyer, Michael Dechant

Br J Haematol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2m(1) antibody.
Christina Brunke, Stefan Lohse, Stefanie Derer, Matthias Peipp, Peter Boross, Michael Dechant

MAbs· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-dependent cellular cytotoxicity in patients on chronic hemodialysis.
Till Koch, Stefanie Derer, Matthias Staudinger, Kai Rossen, Pia Glorius, Michael Dechant

Am J Nephrol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
IgA EGFR antibodies mediate tumour killing in vivo.
Peter Boross, Stefan Lohse, Maaike Nederend, Johannes Hendrik Marco Jansen, Geert van Tetering, Michael Dechant

EMBO Mol Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An IgG3 switch variant of rituximab mediates enhanced complement-dependent cytotoxicity against tumour cells with low CD20 expression levels.
Thies Rösner, Stefanie Derer, Christian Kellner, Michael Dechant, Stefan Lohse

Br J Haematol· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of a mutated IgA2 antibody of the m(1) allotype against the epidermal growth factor receptor for the recruitment of monocytes and macrophages.
Stefan Lohse, Christina Brunke, Stefanie Derer, Matthias Peipp, Peter Boross, Michael Dechant

J Biol Chem· July 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.
Stefanie Derer, Sven Berger, Martin Schlaeth, Tanja Schneider-Merck, Katja Klausz, Michael Dechant

Neoplasia· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII).
Katja Klausz, Sven Berger, Jeroen J Lammerts van Bueren, Stefanie Derer, Stefan Lohse, Michael Dechant

Cancer Sci· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC.
Roland Repp, Christian Kellner, Anja Muskulus, Matthias Staudinger, Sahar Mohseni Nodehi, Michael Dechant

J Immunol Methods· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recombinant dimeric IgA antibodies against the epidermal growth factor receptor mediate effective tumor cell killing.
Stefan Lohse, Stefanie Derer, Thomas Beyer, Katja Klausz, Matthias Peipp, Michael Dechant

J Immunol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of human IgA antibodies on complement-dependent cytotoxicity mediated by combinations of EGF-R-directed antibodies.
Stefan Lohse, Matthias Peipp, Thomas Beyer, Thomas Valerius, Michael Dechant

Arch Immunol Ther Exp (Warsz)· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodies.
Matthias Peipp, Michael Dechant, Thomas Valerius

MAbs· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc-engineered EGF-R antibodies mediate improved antibody-dependent cellular cytotoxicity (ADCC) against KRAS-mutated tumor cells.
Martin Schlaeth, Sven Berger, Stefanie Derer, Katja Klausz, Stefan Lohse, Michael Dechant

Cancer Sci· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Yvonne Guettinger, Karin Barbin, Matthias Peipp, Joerg Bruenke, Michael Dechant

J Immunol· February 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage.
Tanja Schneider-Merck, Jeroen J Lammerts van Bueren, Sven Berger, Kai Rossen, Patrick H C van Berkel, Michael Dechant

J Immunol· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells.
Matthias Peipp, Jeroen J Lammerts van Bueren, Tanja Schneider-Merck, Wim W K Bleeker, Michael Dechant

Blood· September 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effector mechanisms of therapeutic antibodies against ErbB receptors.
Matthias Peipp, Michael Dechant, Thomas Valerius

Curr Opin Immunol· August 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complement-dependent tumor cell lysis triggered by combinations of epidermal growth factor receptor antibodies.
Michael Dechant, Wencke Weisner, Sven Berger, Matthias Peipp, Thomas Beyer

Cancer Res· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor cell killing mechanisms of epidermal growth factor receptor (EGFR) antibodies are not affected by lung cancer-associated EGFR kinase mutations.
Matthias Peipp, Tanja Schneider-Merck, Michael Dechant, Thomas Beyer, Jeroen J Lammerts van Bueren

J Immunol· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effector mechanisms of recombinant IgA antibodies against epidermal growth factor receptor.
Michael Dechant, Thomas Beyer, Tanja Schneider-Merck, Wencke Weisner, Matthias Peipp

J Immunol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study.
Juergen Rech, Roland Repp, Dorit Rech, Bernhard Stockmeyer, Michael Dechant

Leuk Lymphoma· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors.
Marielle A Otten, Esther Rudolph, Michael Dechant, Cornelis W Tuk, Rogier M Reijmers

J Immunol· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis